ClinicalTrials.gg
CompletedNCT03099382Updated Jan 22, 2024Results posted

Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

A Phase 3 interventional study of camrelizumab and Docetaxel in Esophageal Carcinoma, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-01-22.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
457
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing camrelizumab in Esophageal Neoplasms — 5 open to participants now, 6 under way, none of them phase 3. camrelizumab · Esophageal Neoplasms.

Enrollment
2nd of 17
457 · median 63
Started
2017
with 2 others
Phase 3
3 of 17
none open now
Registered
1st of 17
by date
Lead sponsor
3 of 17
Jiangsu HengRui Medicine Co., Ltd.

Among the 17 studies testing camrelizumab in Esophageal Neoplasms, this one is the 2nd largest by enrollment, is one of 3 that started in 2017, is one of 3 in phase 3, and was the 1st registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

5 of the 17 studies testing camrelizumab in Esophageal Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 388 Esophageal Neoplasms studies recruiting now, 246 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing camrelizumab in Esophageal Neoplasms, or all of them as a file.
02

Study summary

In this study, participants with advanced or metastatic squamous cell carcinoma of the esophagus that has progressed after first-line standard therapy will be randomized to receive either single agent SHR-1210 or the Investigator's choice of standard therapy with docetaxel or irinotecan. The primary study hypothesis is that treatment with SHR-1210 will prolong overall survival (OS) as compared to treatment with standard therapy.

03

Conditions studied

  • Esophageal Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. age: 18-75 years, male or female.
  2. or cytologically confirmed Squamous Cell Carcinoma of the Esophagus, locally advanced, unresectable disease, recurrent or disease.
  3. Fail to the standard therapy.
  4. based on (RECIST) 1.1.
  5. Can provide either a newly obtained or sample.
  6. 0-1.
  7. of greater than 12 weeks.
  8. Adequate organ function.
  9. Female: child bearing potential, a negative urine or serum pregnancy test result within 72 h before study treatment. Participants of must be willing to use adequate for the course of the study through 3 months after the last dose of SHR-1210 or through 180 days after the last dose of docetaxel or irinotecan.
  10. Patient has given written .

Exclusion criteria

Exclusion Criteria:

  1. Has a known additional within the last 5 years before study treatment with the exception of curatively treated basal cell and squamous cell carcinoma of the skin and/or curatively resected in-situ cervical and/or breast cancers.
  2. Known central nervous system (CNS) .
  3. Subjects with any active disease or history of autoimmune disease.
  4. Uncontrolled heart disease, including but not limited to the following: (1) > II congestive heart failure; (2) unstable angina, (3) myocardial infarction within the past 1 year; (4) clinically significant supraventricular arrhythmia or ventricular arrhythmia requirement for treatment or intervention;
  5. Active infection or an unexplained fever > 38.5°C before two weeks of randomization (subjects with tumor fever may be enrolled at the discretion of the investigator);
  6. History of Interstitial Pneumonia or received for non-infectious pneumonitis.
  7. Known (HIV) infection, active or .
  8. , \<18.5mg/m2 or ≥10% weight lost before screening.
  9. Prior therapy with a , anti-PD-Ligand 1 (PD-L1) agent.
  10. Known history of to macromolecular protein preparation or any components of the SHR-1210 formulation, allergy, hypersensitivity, or to docetaxel, or irinotecan.
  11. Concurrent medical condition requiring the use of cortisol ( >10mg/day Prednisone or equivalent dose) or other systematic medications within 14 days before the study treatment. Except: inhalation or topical corticosteroids. Doses > 10 mg/day prednisone or equivalent for replacement therapy.
  12. Has received prior anti-cancer monoclonal antibody (mAb), chemotherapy, targeted small molecule therapy, or radiation therapy within 4 weeks prior to study Day 1 or not recovered from adverse events due to a previously administered agent.
  13. Currently participating or has participated in a study within 4 weeks of the first dose of study medication.
  14. Received a within 4 weeks of the first dose of study medication.
  15. Pregnancy or breast feeding.
  16. According to the investigator, other conditions that may lead to stop the research.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
457 participants (actual)

Study arms

  • Experimental
    camrelizumab

    Biological: camrelizumab

  • Active comparator
    Investigator's Choice of Standard Therapy

    Docetaxel or Irinotecan

    Drug: Docetaxel · Drug: Irinotecan

Interventions

  • Biologicalcamrelizumab

    Subjects receive camrelizumab intravenous infusion at the dose 200mg on Day 1 every 2 weeks

    Also known as: SHR-1210

  • Subjects receive Docetaxel intravenous infusion at the dose 75mg/m2 on Day 1 every 3 weeks

  • Subjects receive Irinotecan intravenous infusion at the dose 180mg/m2 on Day 1 every 2 weeks

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Time frame: approximately 24 months

07

Results

Posted Jan 22, 2024

Participant flow

Participant flow — Overall Study
MilestoneCamrelizumabInvestigator's Choice of Standard Therapy
Started228220
Completed226217
Not completed23
Withdrew: Protocol violation23

Outcome measures

PrimaryOverall Survival (OS)
Time frame:
approximately 24 months
Reported as:
Median · months
Overall Survival (OS)
monthsCamrelizumabInvestigator's Choice of Standard Therapy
Overall Survival (OS)8.28 (6.77 to 9.72)6.24 (5.68 to 6.93)

Adverse events

Collected over approximately 24 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Camrelizumab23/228 (10.1%)71/228 (31.1%)226/228 (99.1%)
Investigator's Choice of Standard Therapy10/220 (4.5%)52/220 (23.6%)210/220 (95.5%)
Most frequent serious events
Showing 10 of 84
Most frequent serious events
EventCamrelizumabInvestigator's Choice of Standard Therapy
PneumonitisRespiratory, thoracic and mediastinal disorders9/2283/220
Lung InfectionInfections and infestations7/2287/220
Decreased AppetiteMetabolism and nutrition disorders1/2286/220
White Blood Cell Count DecreasedInvestigations0/2286/220
VomitingGastrointestinal disorders0/2285/220
DeathGeneral disorders5/2283/220
DysphagiaGastrointestinal disorders4/2281/220
Hepatic Function AbnormalHepatobiliary disorders4/2281/220
Reactive Cutaneous Capillary Endothelial ProliferationSkin and subcutaneous tissue disorders4/2280/220
Upper Gastrointestinal HaemorrhageGastrointestinal disorders2/2283/220
Most frequent other events
Showing 10 of 52
Most frequent other events
EventCamrelizumabInvestigator's Choice of Standard Therapy
Reactive cutaneous capillary endothelial proliferationSkin and subcutaneous tissue disorders181/2280/220
White blood cell count decreasedInvestigations33/228112/220
AnaemiaBlood and lymphatic system disorders102/228107/220
NauseaGastrointestinal disorders19/22887/220
Decreased appetiteMetabolism and nutrition disorders44/22880/220
DiarrhoeaGastrointestinal disorders31/22878/220
AstheniaGeneral disorders54/22875/220
Neutrophil count decreasedInvestigations17/22875/220
VomitingGastrointestinal disorders19/22864/220
CoughRespiratory, thoracic and mediastinal disorders52/22831/220

Baseline characteristics

Age, Continuous
Age, Continuous(years)CamrelizumabInvestigator's Choice of Standard TherapyTotal
Mean59.3 ± 7.4659.5 ± 6.6859.4 ± 7.08
Sex: Female, Male
Sex: Female, Male(Participants)CamrelizumabInvestigator's Choice of Standard TherapyTotal
Female202848
Male208192400
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CamrelizumabInvestigator's Choice of Standard TherapyTotal
American Indian or Alaska Native000
Asian228220448
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)CamrelizumabInvestigator's Choice of Standard TherapyTotal
China228220448
08

Study locations

2 sites
  • 307 Hospital of PLA
    Beijing, Beijing, China
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing, China
09

References and documents

Publications

  • Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, Chen J, Zhang H, Niu Z, Fan Q, Lin L, Gu K, Liu Y, Ba Y, Miao Z, Jiang X, Zeng M, Chen J, Fu Z, Gan L, Wang J, Zhan X, Liu T, Li Z, Shen L, Shu Y, Zhang T, Yang Q, Zou J; ESCORT Study Group. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020 Jun;21(6):832-842. doi: 10.1016/S1470-2045(20)30110-8. Epub 2020 May 13. PubMed 32416073 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in May 2019, 24 months.

Results were first posted in Jan 2024, 4 years 8 months after primary completion.

Of 57 phase 3 interventional studies under Esophageal Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 113. This study's 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2017
First posted
Apr 4, 2017
StartActual
May 5, 2017
Primary completionActual
May 6, 2019
CompletionActual
May 6, 2019
Results first posted
Jan 22, 2024
Last update
Jan 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03099382
Responsible party
Sponsor
First posted
Apr 4, 2017
Start date
May 5, 2017
Primary completion
May 6, 2019
Completion
May 6, 2019
Results posted
Jan 22, 2024
Last update
Jan 22, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camrelizumab

Start the discussion